(Q30383418)

English

Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch. (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

0 references

influenza vaccine

1 reference

based on heuristic

inferred from title

author name string

Gregory M Glenn

1

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

D Nigel Thomas

2

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Kimber L Poffenberger

3

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

David C Flyer

4

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Larry R Ellingsworth

5

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Bo H Andersen

6

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Sarah A Frech

7

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

language of work or name

0 references

publication date

1 December 2009

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

27 Suppl 6

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

G60-6

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Use of cumulative incidence of novel influenza A/H1N1 in foreign travelers to estimate lower bounds on cumulative incidence in Mexico

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Influenza vaccine supply: building long-term sustainability.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Pandemic influenza vaccines: meeting the supply, distribution and deployment challenges

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Current status and progress of prepandemic and pandemic influenza vaccine development.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Emulsion-based adjuvants for influenza vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Vaccines for seasonal and pandemic influenza.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Controlled, single-step, stratum corneum disruption as a pretreatment for immunization via a patch

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Immunostimulant patch enhances immune responses to influenza virus vaccine in aged mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Immunostimulant patch containing heat-labile enterotoxin from Escherichia coli enhances immune responses to injected influenza virus vaccine through activation of skin dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Prioritization of pandemic influenza vaccine: rationale and strategy for decision making.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Trivalent inactivated subunit influenza vaccine Influvac: 25-Year experience of safety and immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Response to a monovalent 2009 influenza A (H1N1) vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Correlated Studies of a Recombinant Influenza-Virus Vaccine. III. Protection against Experimental Influenza in Man

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Efficacy of Purified Influenza Subunit Vaccines and Relation to the Major Antigenic Determinants on the Hemagglutinin Molecule

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Protection of infants from infection with influenza A virus by transplacentally acquired antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.031

7 January 2021

Identifiers

10.1016/J.VACCINE.2009.10.031

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30383418&oldid=1984424044"